TP53 Mutation Lung Cancer: 19 Real Stories

19 stories match lung cancer and TP53 mutation. 17 of them mention chemotherapy.

Cancer Stories

Shannon, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Shannon's Survivor Story

Patient Info: Shannon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: cervical spine (C1/C2 and C4/C6), liver

As of June 2026, Shannon described no evidence of active disease: visible tumors were gone, the original lung mass had decreased from 10.8 cm to a 3.8 cm cavity, and targeted therapy continued to suppress possible remaining cells.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR-mutated lung adenocarcinoma with suspected myocardial metastasis responding to afatinib plus chemotherapy

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR L861Q; PD-L1 TPS/CPS 65%. TP53, MET and PIK3CA alterations also reported.

Metastatic Site: left ventricular myocardium; mediastinal lymph nodes…

As of December 2025, the suspected left-ventricular myocardial metastasis had shrunk after 2 courses of afatinib plus pemetrexed/cisplatin, and the patient had no cardiovascular events during monitoring.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA KRAS/STK11/TP53-mutated lung adenocarcinoma: fatal pembrolizumab-induced myocarditis after adjuvant therapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Ki-67 20-25%; PD-L1 expression 10%; KRAS exon 2 mutation; STK11 mutation; TP53 mutation

As of December 2025, he had died after 15 days of hospitalization from sepsis and multi-organ failure following severe pembrolizumab-induced myocarditis after adjuvant treatment for resected Stage IIIA lung adenocarcinoma.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IVB SMARCA4-deficient NSCLC with brain metastasis: stable disease after surgery, radiation, chemotherapy, immunotherapy, and bevacizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: SMARCA4/BRG-1 loss with TP53 and other mutations; TMB high; PD-L1 <1%; MSI-H not detected.

Metastatic Site: brain

As of October 2025, the patient had stable disease, no brain recurrence, a controlled left lower-lobe lung lesion, and manageable treatment toxicity while continuing bevacizumab plus pemetrexed maintenance.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic lung adenocarcinoma with brain and iliac bone response to chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1-negative; no EGFR, ALK, ROS1, RET, KRAS, BRAF, MET, HER2, or NTRK alteration detected; TP53 mutation found.

Metastatic Site: left iliac bone, brain

Brain metastases achieved complete remission without cranial irradiation, and lung, bone, and brain lesions remained stable at last follow-up, with PFS of 35 months and OS exceeding 40 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA squamous lung cancer with pathologic complete response after immunochemotherapy

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: PD-L1 TPS 90%; PD-L1 CPS 100%; EGFR p.G719S 24.9%; EGFR p.S768I 24.6%; TP53 p.S183* 7.2%; TMB 0.0 Muts/Mb

Systematic imaging in March 2025 showed no recurrence or metastasis, with postoperative disease-free survival longer than 30 months and overall survival longer than 34 months.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV Lung Adenocarcinoma Presenting as Persistent Chest Pain and Rib Metastasis

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: TP53 mutation; PD-L1 30%; no sensitive driver mutation identified

Metastatic Site: bone

After delayed diagnosis of Stage IV lung adenocarcinoma with a painful rib metastasis, he began systemic immunotherapy and local treatment for the painful bone lesion.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

HER2 exon 20 metastatic lung adenocarcinoma with pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 exon 20 insertion lung adenocarcinoma with TP53 mutation, PD-L1 TPS 50%, and low TMB.

Metastatic Site: contralateral lung

Right lower lobectomy with radical lymphadenectomy in November 2023 showed pathologic complete response, and no additional therapy was offered after surgery.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 RET-rearranged lung cancer: complete pathologic response to pralsetinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: KIF5B-RET rearrangement; TP53 missense mutation; PD-L1-negative; CK7-positive; TTF-1-positive; Ki-67 70%

Metastatic Site: pleura, mediastinal lymph nodes, hilar lymph nodes

After pralsetinib response and surgery, pathology showed no residual viable tumor in the lung primary, pleural nodules, or sampled lymph nodes; she continued adjuvant pralsetinib.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Advanced Non-Small Cell Lung Cancer With ERBB2 and TP53 Mutations

Patient Info: Anonymized, male, 50s | Stage IV

Biomarkers: ERBB2 exon 20 Y772-A775dup mutation; TP53 mutation; PD-L1 TPS 0%

Metastatic Site: liver, bone, both lungs

Imaging after treatment showed stable disease, and he remained in good condition while continuing maintenance pemetrexed and bevacizumab.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV PD-L1-negative lung adenocarcinoma: complete response with nivolumab and ipilimumab

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: PD-L1-negative; no targetable molecular alterations on DNA/RNA next-generation sequencing; TP53 alteration reported at 66%

Metastatic Site: left pleural effusion; right adrenal gland;…

As of February 2024, she remained on maintenance nivolumab and ipilimumab after 14 cycles, without significant toxicity and with persistent complete response of Stage IV PD-L1-negative lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

EGFR-mutant lung adenocarcinoma in Li-Fraumeni syndrome: relapse-free after lobectomy and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Lung tumor had EGFR exon 19 deletion. Germline TP53 variant was consistent with Li-Fraumeni syndrome; prior breast cancers were HER2 positive.

As of July 2024, she was free of relapse 2 years after left inferior lobectomy and pemetrexed/cisplatin for EGFR exon 19 deletion lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: MET exon 14 skipping, TP53 and BRAF mutations; PD-L1 expression 5%

Metastatic Site: pleura; mediastinal lymph node

Savolitinib produced a partial radiological response, but surgery confirmed persistent pleural and mediastinal nodal metastases with ypStage IVA disease. He recovered and continued adjuvant savolitinib.

PubMed Central
OutcomeIn Treatment